BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17509993)

  • 1. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease.
    Manco M; Marcellini M; Giannone G; Nobili V
    Am J Clin Pathol; 2007 Jun; 127(6):954-60. PubMed ID: 17509993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
    Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
    J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between the severity of liver damage and the serum leptin level for nonalcoholic fatty liver disease].
    Kim KO; Park SH; Park CH; Han TH; Yoo KS; Kim JH; Lee MS; Kim DJ; Park CK; Cho HD
    Korean J Hepatol; 2005 Mar; 11(1):51-8. PubMed ID: 15788885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
    Musso G; Gambino R; Bo S; Uberti B; Biroli G; Pagano G; Cassader M
    Diabetes Care; 2008 Mar; 31(3):562-8. PubMed ID: 18056890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease.
    Nobili V; Siotto M; Bedogni G; Ravà L; Pietrobattista A; Panera N; Alisi A; Squitti R
    J Pediatr Gastroenterol Nutr; 2013 Apr; 56(4):370-5. PubMed ID: 23154483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease.
    Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE
    Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis.
    Hashem RM; Mahmoud MF; El-Moselhy MA; Soliman HM
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):995-1001. PubMed ID: 18787467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
    Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
    Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.
    Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease.
    Fotiadu A; Gagalis A; Akriviadis E; Kotoula V; Sinakos E; Karkavelas G; Hytiroglou P
    Pathol Int; 2010 Feb; 60(2):87-92. PubMed ID: 20398192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha.
    Chu CJ; Lu RH; Wang SS; Chang FY; Wu SL; Lu CL; Chun BC; Chang CY; Wu MY; Lee SD
    Hepatogastroenterology; 2007; 54(79):2099-102. PubMed ID: 18251167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis.
    Miyaaki H; Ichikawa T; Nakao K; Yatsuhashi H; Furukawa R; Ohba K; Omagari K; Kusumoto Y; Yanagi K; Inoue O; Kinoshita N; Ishibashi H; Yano M; Eguchi K
    Liver Int; 2008 Apr; 28(4):519-24. PubMed ID: 17976158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.